Dr. Hoffman currently serves as Chief Executive Officer of Aerpio Pharmaceuticals, Inc., a public biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Prior to that, he served as Senior Advisor of PDL BioPharma, Inc., where he focused on product acquisition and structured debt and royalty monetization opportunities. Dr. Hoffman played a major role in portfolio company development at Skyline Ventures, a venture capital firm, where he served as Managing Director, and as a General Partner at TVM Capital. Dr. Hoffman served as President, Chief Executive Officer and a Director of Allos Therapeutics, Inc. where he remained as Chairman until its acquisition by Spectrum Pharmaceuticals, Inc. Dr. Hoffman currently serves on the Board of Directors of Dicerna Pharmaceuticals, Inc., and AcelRx Pharmaceuticals, Inc. Dr. Hoffman completed a fellowship in clinical oncology and a residency and fellowship in dermatology, both at the University of Colorado. He holds a Ph.D. in chemistry from Northwestern University and an M.D. from the University of Colorado School of Medicine.
Dr. Haluska has served as CEO of Anchiano (formerly BioCanCell) since October 2016. He most recently served as Chief Medical Officer and Senior Vice President of Clinical R&D at ARIAD Pharmaceuticals, Inc., where he held overall responsibility for clinical development strategy. At ARIAD he led the clinical development and approval of ponatinib (marketed as Iclusig) in the US, EU and other territories, as well as the development of brigatinib (marketed as Alunbrig) approved in the US by the FDA.
Dr. Haluska graduated from Harvard College and the University of Pennsylvania School of Medicine, undertook medical training at Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI), and a fellowship at the Massachusetts Institute of Technology Center for Cancer Research. He became assistant professor of medicine at Harvard Medical School, and leader of the melanoma research programs at the MGH Cancer Center and the DFCI through the Dana-Farber Harvard Cancer Center. Subsequently he was deputy director of the Tufts New England Medical Center Cancer Center. He currently serves on the Board of Directors at Vedantra Pharmaceuticals.
Ms. Alon is the founder and CEO of Medstrada Israel. Between 1997 and 2016, Ms. Alon served as a General Partner of Pitango Venture Capital. Prior to her tenure at Pitango, Ms. Alon held senior positions with Montgomery Securities from 1981 to 1987, Genesis Securities, LLC from 1993 to 1996, and Kidder Peabody & Co. from 1987 to 1993, as well as managing her own medical device independent consulting business in San Francisco from 1995 to 1996. Ms. Alon was the Founder and Chairperson of Israel Life Science Industry, a not-for-profit organization then representing the mutual goals of approximately 700 Israeli life science companies. She is also the Co-Founder of IATI, Israel Advanced Technology Industries, an umbrella organization for all high-tech and life sciences companies in Israel. She has a B.A. in Economics from the Hebrew University of Jerusalem, Israel and an M.B.A. from Boston University.
Mr. Connelly is a seasoned biotech executive having served in senior management roles, including CEO and Board member, for several biotechnology companies. Most recently, Mr. Connelly was a Venture Partner with Flagship Pioneering. During this same time, Mr. Connelly was Chief Executive Officer of Axcella Health, Inc., a clinical-stage therapeutics company developing endogenous modulators of metabolism to treat an array of serious diseases. He rebuilt Axcella with an amino acid therapeutic focus leading to multiple clinical stage programs in muscle, metabolic and neurological diseases. Mr. Connelly was Chief Executive Officer of Pulmatrix, Inc., a pharmaceutical company developing inhaled drugs for respiratory diseases. Prior to Pulmatrix, he became founding Chief Executive Officer & first employee of Domantis, a UK-based biotech building a novel fully-human antibody fragment platform and pipeline, leading the company to its acquisition by Glaxo SmithKline PLC in 2007 for $454 million in cash, the largest all-cash value paid for a preclinical biotechnology company. He spent the first 12 years of his career with Abbott Laboratories. Mr. Connelly has served on the Board of Directors for WikiCell Designs, Kaliedo and Kintai, and has chaired the Board of Directors for Aero Designs. He received a B.S. in Business Administration from the University of Florida.
Mr. Hardy is the co-founder and CEO of Brickell Biotech, Inc., a pharmaceutical company focused on developing novel drugs for the treatment of skin diseases. Prior to Brickell, he was the co-founder and President of Concordia Pharmaceuticals, Inc. an oncology drug development company acquired by Kadmon Corporation in 2011. From 1992 to 1998, he was President of SANO Corporation, a pharmaceutical company that he co-founded, focused on the development of novel transdermal drug delivery systems that was acquired by Elan Corporation in 1998. Prior to SANO, Mr. Hardy held various corporate roles with IVAX Corporation, Key Pharmaceuticals, and Hoechst-Roussel Pharmaceuticals, Inc. He earned his B.S. degree in Pharmacy from the University of North Carolina – Chapel Hill and M.B.A. from UNC – Greensboro.
Dr. Howard has served as a director since September 2016 and was Chairman of the Board between February 2017 and November 2018. He has been a Senior Managing Director of Hudson Ventures since 1996. After practicing medicine from 1981 to 1988, he co-founded Presstek, Inc., a publicly-held graphic arts technology company whose market value grew from $12 million to over $800 million under his direction. Dr. Howard served as President and CEO of Presstek from 1987 until 1992, and served on the Presstek Board of Directors for over twenty years. He was a Clinical Professor in the Department of Psychiatry at the Morsani College of Medicine at the University of South Florida, and the Entrepreneur-in-Residence and an Adjunct Professor at the University of South Florida Center for Entrepreneurship. In addition, Dr. Howard has worked since 2012 as a consultant to The Villages, the largest retirement community in the U.S., assisting them in building a “state of the art” healthcare delivery system. Dr. Howard currently serves as Chairman of the Board of Directors of iCAD, inc., also a publicly-held company, and the University of New Hampshire Foundation Board of Trustees. He holds a B.Sc. degree from the University of New Hampshire and an M.D. degree from New York Medical College.
Mr. Kohlberg has served as a director since February 2017. He is the Senior Associate Provost and Chief Technology Development Officer of Harvard University. Previously, he was CEO of the Tel Aviv University Economic Corporation and CEO of RAMOT at Tel Aviv University. He served as Vice President at New York University Medical Center and Vice Provost of New York University. He also served as the Managing Director of Yeda R&D Company of the Weizmann Institute of Science.
Mr. Kohlberg received his M.B.A. from INSEAD and LL.B. from Tel Aviv University.
Ms. Makov was Chief Financial Officer of Alvarion Ltd. Prior to Alvarion, she served as the Chief Financial Officer of Aladdin Knowledge Systems Ltd. where she was responsible for the finance, operations, information systems and human resources functions. She served as Vice President of Finance at Check Point Software Technologies Ltd. and as Director of Finance for NUR Macroprinters Ltd., after having spent seven years in public accounting with Arthur Andersen in various senior financial positions in its New York, London and Tel Aviv offices. She serves as a Director on the Board of BioLight Life Sciences Ltd. and its subsidiaries. She is an Israel and U.S. Certified Public Accountant. Ms. Makov holds a B.A. in Accounting and Economics from Tel Aviv University.
Mr. Veru serves as Chief Investment Officer and Co-Chairman of Palisade Capital Management, LLC, an asset management firm based in Fort Lee, New Jersey. In this capacity, he has oversight responsibilities for all of Palisade’s investment strategies that trade publicly traded securities. Mr. Veru became associated with Palisade’s partners in 1984 at Drexel Burnham Lambert and later at Smith Barney, where he held a variety of analytical positions. From 1992 through 1999, he was President and Director of Research at Awad Asset Management, a division of Raymond James & Associates. Dan rejoined his colleagues at Palisade in 2000 as Chief Investment Officer. A graduate of Franklin & Marshall College, Dan has appeared as a guest on CNBC, Bloomberg News, and Fox News. He also contributes market opinions to various financial publications.